Stephen Slade, MD, Honored with 2016 PTV Star of Texas Healthcare Award
INTERNATIONALLY RENOWNED OPHTHALMIC THOUGHT LEADER RECOGNIZED FOR OUTSTANDING SERVICE TO TEXAS HEALTHCARE COMMUNITY
Austin, TX – September 27, 2016 – PTV Healthcare Capital announced today that Dr. Stephen Slade, a thought leader, innovator, and educator in the field of refractive surgery, has been awarded the 2016 Star of Texas Healthcare Award. Dr. Slade accepted the award last week at PTV’s 2016 Investor Meeting in Austin, Texas.
For the past nine years, the Star of Texas Healthcare award has honored healthcare professionals and outstanding members of the Texas community for their commitment to healthcare improvement and innovation through either professional achievement or outstanding philanthropic service. Previous recipients of the Star of Texas Healthcare Award include On-X Life Technologies, Inc., a leading manufacturer of mechanical heart valve replacements that was acquired by CryoLife in January 2016; Mack Brown, former coach of the Texas Longhorns football team; John Mendelsohn, MD, Past-President of the MD Anderson Cancer Center; Steven McKnight, PhD, Professor and Chairman of the Department of Biochemistry at the University of Texas Southwestern; Mark McClellan, MD, PhD, former Commissioner of the US FDA for Medicare and Medicaid Services; Julio C. Palmaz, MD, inventor of the first commercially successful coronary stent; James T. Willerson, MD, President and Medical Director for the Texas Heart Institute; and Francisco G. Cigarroa, MD, Chancellor of the University of Texas System.
Dr. Slade, a specialist in Presbyopia correction, cataract surgery, LASIK, implantable contact lenses (ICL), and refractive surgery, is a Houston native whose private practice is also located in Houston, Texas. In 1991, along with Stephen Brint, MD, Dr. Slade performed the first LASIK in the United States. Later he performed the first Custom LASIK ablation based on topography in the United States. He has since done tens of thousands of cases. He is an active teacher of surgical techniques and has taught, lectured to, and certified over 8,000 surgeons on LASIK and lamellar refractive surgery.
Dr. Slade has remained on the cutting edge, having the nation’s longest experience with Laser Cataract Surgery, All Laser LASIK, accommodating IOLs (Crystalens) and ICL. Dr. Slade was a lead investigator and presented the data to the FDA for panel approval for both the Crystalens and the ICL. Of unique note, Dr. Slade is considered a “surgeon’s surgeon”. Over 450 of his fellow eye surgeons have chosen him for their own eye surgery. He is an active researcher and the United States medical monitor for several new technologies including the IntraLase laser for All Laser LASIK, the implantable corneal contact lens, and the WaveLight laser.
Dr. Stephen Slade accepts the 2016 Star of Texas Healthcare Award at the PTV Investor Meeting Thursday, September 22, 2016.
In 2007, Dr. Slade received the Barraquer Award, the highest award from the largest society of refractive surgeons. The Barraquer Award is given only once a year to one doctor in the world. Dr. Slade was selected by his peers for both “Best Doctors” and “Best Doctors in America” and has received the Honor Award of the American Academy of Ophthalmology. He is a regular presenter at medical meetings and has received several “Best Speaker” awards and has twice won First Place at the American Society of Cataract and Refractive Surgery Film Festival. He has received numerous other awards including 11 named lectures, Refractive Surgeon of the Year, two China Service Medals, Summit Technologies Pioneer of Refractive Surgery Award, Casebeer Award and Lans Lectureship.
Dr. Slade has produced many articles and book chapters, holds four patents or patents pending in the field, and has authored nine textbooks on refractive surgery. He has served on several Editorial Boards including the Journal of Refractive Surgery. He has been featured in numerous news segments aired on CBS, ABC and PBS as well as numerous national affiliate stations. Dr. Slade has been quoted in the New York Times and the Wall Street Journal as well as numerous local press stories. Dr. Slade was the featured surgeon on the Emmy Award winning PBS documentary “20/10 by 2010?” narrated by Walter Cronkite.
Dr. Slade attended Tulane University and the University of Texas Medical School with a final, elective year spent at Guy’s Hospital, London, graduating summa cum laude, with highest honors. He completed a residency at the LSU Eye Center in New Orleans and fellowships in corneal surgery at Baylor College of Medicine in Houston and in New York, New York on Project ORBIS. He is a Fellow of the American Academy of Ophthalmology and the American College of Surgeons. Dr. Slade was elected the president of American College of Ophthalmic Surgery in January of 2011 and was also named a Leading Ophthalmologist in America by Becker’s ASC Review. Dr. Slade is the current chairman of the board for the American European Congress of Ophthalmic Surgery (AECOS). AECOS is an international organization of progressive ophthalmologists, dedicated to advancing vision care and improving patients’ quality of life through innovation, education and advocacy. Dr. Slade has also been a member of the PTV Scientific Advisory Board since 2008.
“Dr. Slade is a thought leader in his field and his contributions have irrevocably shaped the lives of millions of patients,” said PTV Founding Managing Director Matt Crawford. “We are honored to be able to recognize his outstanding contributions to healthcare innovation.”
Congratulations to Dr. Slade on this well deserved recognition!
PTV is a healthcare venture capital and growth equity firm dedicated to enabling healthcare entrepreneurs and global innovation. It is comprised of a highly collaborative team of professionals, deeply experienced as investors and operators of life science companies. PTV focuses on mid-to-late stage companies with comparatively low technical, regulatory, and financial risk that are “with the grain” of healthcare economics – improving patient outcomes while decreasing costs – in markets with significant unmet clinical needs.